Abstract
The corneal toxicity of 2 intraocular pressure-lowering agents was compared in a rabbit cornea model with New Zealand White rabbits. Corneal epithelial morphology and cell size were assessed by in vivo confocal microscopy. Baseline microscopic examinations were performed on 1 eye of each animal. Two weeks later, the eyes were bathed for 3 min in travoprost 0.004% preserved without benzalkonium chloride (BAK) or latanoprost 0.005% preserved with 0.02% BAK; the eyes were then rinsed with balanced salt solution, and the corneas were again examined by confocal microscopy (n=4/group). A second group of animals was exposed to the medications through a dosing regimen of 1 drop/min (3 drops total) (n=4/group). In eyes treated with travoprost without BAK (3-min bath), superficial epithelial cells were similar to baseline, as indicated by their visible cell borders and bright nuclei. In contrast, the surface cells in eyes treated with latanoprost were significantly smaller and brighter and had less distinct borders. Surface cell size was significantly smaller as compared with baseline size and as compared with rabbits treated with travoprost without BAK for 3 min. Similar effects on corneal epithelial cell morphology were observed with the 1-drop/min dosing regimen. In this rabbit model, travoprost 0.004% preserved without BAK did not cause corneal epithelial toxicity; latanoprost 0.005% induced superficial cell loss, most likely caused by the presence of a relatively high concentration of BAK (0.02%).
Similar content being viewed by others
References
Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review.Am J Health Syst Pharm. 2005; 62: 691–699.
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020.Br J Ophthalmol. 2006; 90: 262–267.
Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.Arch Ophthalmol. 2006; 124: 12–19.
Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.BMJ. 2005; 331: 134.
Singh A. Medical therapy of glaucoma.Ophthalmol Clin North Am. 2005; 18: 397–408.
Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva.Br J Ophthalmol. 1993; 77: 590–596.
Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.Arch Ophthalmol. 1994; 112: 1446–1454.
Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.Invest Ophthalmol Vis Sci. 2005; 46: 2444–2450.
Kuppens EV, de Jong CA, Stolwijk TR, de Keizer RJ, van Best JA. Effect of timolol with and without preservative on the basal tear turnover in glaucoma.Br J Ophthalmol. 1995; 79: 339–342.
Fisher AA. Allergic contact dermatitis and conjunctivitis from benzalkonium chloride.Cutis. 1987; 39: 381–383.
Baudouin C. Allergic reaction to topical eyedrops.Curr Opin Allergy Clin Immunol. 2005; 5: 459–463.
De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.Curr Eye Res. 2000; 20: 85–94.
Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears.Ophthalmology. 1992; 99: 873–878.
Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.Br J Ophthalmol. 1998; 82: 39–42.
Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface.Curr Eye Res. 1998; 17: 419–425.
Kovoor TA, Kim AS, McCulley JP, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy.Eye Contact Lens. 2004; 30: 90–94.
Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride.Cornea. 1992; 11: 221–225.
Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface.Curr Opin Ophthalmol. 1996; 7: 80–86.
Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies.Ophthalmology. 1999; 106: 556–563.
Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.Invest Ophthalmol Vis Sci. 2004; 45: 1360–1368.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Whitson, J.T., Cavanagh, H.D., Lakshman, N. et al. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Therapy 23, 663–671 (2006). https://doi.org/10.1007/BF02850305
Issue Date:
DOI: https://doi.org/10.1007/BF02850305